Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Feb 10, 2011


Title: Retroviral Vectors for Delivery of Interfering RNA

Patent Number: 7,884,200

Filed: Oct. 7, 2009

Lead Inventor: Dorre Grueneberg, Aventis Pharmaceuticals

The patent, its abstract states, claims “retroviral vectors for delivering interfering RNA into cells.”

Title: RNA Interference-Mediating Small RNA Molecules

Application Number: 20110027883

Filed: June 21, 2010

Lead Inventor: Thomas Tuschl, Max Planck Institute

“Double-stranded RNA induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference,” the patent application's abstract states. “Using a Drosophila in vitro system, we demonstrate that 19-23 [nucleotide-long] short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3' ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA.

“Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced [small interfering ribonucleoprotein particle] complex,” the abstract adds.

Title: Novel siRNA Compounds for Inhibiting RTP801

Application Number: 20110028531

Filed: March 17, 2009

Lead Inventor: Elena Feinstein, Quark Pharmaceuticals

The invention, the patent application's abstract states, comprises “chemically modified siRNA compounds that target RTP801 and pharmaceutical compositions comprising same useful for treating microvascular disorders, eye diseases, hearing impairment, neurodegenerative diseases and disorders, spinal cord injury, and respiratory conditions.”

Title: Methods of Treating Eye Diseases in Diabetic Patients

Application Number: 20110028532

Filed: June 7, 2010

Lead Inventor: Elena Feinstein, Quark Pharmaceuticals (Silence Therapeutics)

The invention, the patent application's abstract states, comprises “novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases, and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.”

Title: RNAi Inhibition of CTGF for Treatment of Ocular Disorders

Application Number: 20110028534

Filed: Oct. 8, 2010

Lead Inventor: Allan Shepard, Alcon

“RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression,” the patent application's abstract states. “Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy, and wound healing. Such disorders are treated by administering interfering RNAs of the ... invention.”

Title: Methods and Compositions Capable of Causing Post-Transcriptional Silence of Gene Expression in a Synergic Manner

Application Number: 20110030075

Filed: Jan. 29, 2009

Lead Inventor: Xabier Abad Lloret, Proyecto De Biomedicina Cima

“The invention relates to compositions for the post-transcriptional inhibition of gene expression by means of the combined use of a modified U1 snRNA targeted at a pre-selected region in a target pre-mRNA and of a gene expression-silencing agent of the siRNA, shRNA and/or miRNA type, as well as the use of said combinations for the treatment of diseases caused by the unwanted over-expression of a protein,” the patent application's abstract states.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.